A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: JNJ-31001074 3 mg/d
Drug: JNJ-31001074 1 mg/d
Drug: JNJ-31001074 10 mg/d
Drug: Atomoxetine 80 mg/d
Drug: OROS methylphenidate HCl 54 mg/d
Drug: Placebo

Registration Number: NCT00880217

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety/tolerability of 3 different dosages of JNJ-31001074 compared with placebo in adult patients with attention-deficit/hyperactivity disorder (ADHD).

Detailed Description: This will be a randomized (study drug assigned by chance), double-blind (neither the investigator nor the patient know the name of the assigned study drug), placebo- and active-controlled, parallel-group, multicenter study in patients with adult ADHD. The study population will include approximately 426 male and female patients, 18 to 55 years of age (inclusive) with a DSM-IV diagnosis of ADHD, who will be randomly assigned (like flipping a coin) in a 1:1:1:1:1:1 ratio to 1 of 6 treatment groups (1 milligrams per day \[mg/d\] JNJ-31001074, 3 mg/d JNJ-31001074, 10 mg/d JNJ 31001074, 80 mg/d atomoxetine HCl, 54 mg/d controlled-release \[OROS\] methylphenidate HCl, or placebo). Study centers will make every attempt to include approximately 4 women for every 10 men randomized. The study will consist of 3 phases: a screening phase of up to 7 days; a 42-day double-blind treatment phase; and a 7-day post-treatment phase, in which the investigator staff will call patients 7 days after the last dose of study drug, to ask about any adverse events. The total duration of patient participation will be approximately 8 weeks. During the screening and double-blind treatment phases, patients will have periodic assessments at visits (screening, Day 1, Day 4, Day 7, Day 14, Day 28, and Day 42) of the following: severity of ADHD symptoms, including inattention and impulsivity; daily function; sleep experience; and cigarette consumption and cigarette craving. In addition, patients will be asked to include an adult household member to complete the observer version of the Conners Adult ADHD Rating Scale (CAARS-O:SV) at the beginning and end of the study. Patients will take one oral capsules each day in the morning upon awakening, either JNJ-31001074 (1, 3, or 10 mg), matching atomoxetine HCL (40 or 80 mg), matching OROS methylphenidate HCl (36 or 54 mg), or matching placebo. For atomoxetine HCl, patients will receive 40 mg/d for the first 3 days, and 80 mg/d for the remainder of the study. For OROS methylphenidate HCl, patients will receive 36 mg/d for the first 3 days, and 54 mg/d for the remainder of the study.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 430

Inclusion Criteria

Patients diagnosed with ADHD, confirmed with the Conners Adult ADHD Diagnostic Interview for Diagnostic and Statistical Manual, 4th edition (DSM-IV) (CAADID)
Patients who meet the cutoff scores for the Conners Adult ADHD Rating Scale (CAARS-S:SV)
Patients with a Clinical Global Impression - Severity (CGI-S) score of >=4 out of 7
Patients must have a body mass index between 18.0 and 35.0 (inclusive)
Women must be postmenopausal for >=2 years, surgically sterile, abstinent, or practice a double-barrier method of birth control in addition to any other forms of birth control
Women of childbearing potential must have a negative pregnancy test at screening
Men must agree to use a double-barrier method of birth control and to not donate sperm during the study and for 3 months after the last dose of study drug
Female partners of male patients must be postmenopausal, surgically sterile, abstinent, or also use an effective method of birth control.

Exclusion Criteria

Patients with any current Axis I psychiatric disorder
Patients with a diagnosis of autism or Asperger's syndrome
Patients with motor tics or a family history or diagnosis of Tourette's syndrome
Patients with a diagnosis of a primary sleep disorder
Patients who are suicidal or have previously attempted suicide
Patients with a history of substance abuse or dependence within 6 months prior to screening
Patients who have taken any mood stabilizer, antipsychotic, antidepressant, or anxiolytic within 3 months prior to screening
Patients who have started behavioral or cognitive behavioral therapy specifically for ADHD within 3 months prior to screening
Patients who have not responded previously to treatment with a psychostimulant medication or to treatment with atomoxetine HCl or OROS methylphenidate HCl.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
002	JNJ-31001074 3 mg/d	JNJ-31001074 3 mg/d 3-mg capsule once daily for 42 days
001	JNJ-31001074 1 mg/d	JNJ-31001074 1 mg/d 1-mg capsule once daily for 42 days
003	JNJ-31001074 10 mg/d	JNJ-31001074 10 mg/d 10-mg capsule once daily for 42 days
004	Atomoxetine 80 mg/d	Atomoxetine 80 mg/d 40-mg capsule for 3 days followed by 80-mg capsule once daily for 39 days
005	OROS methylphenidate HCl 54 mg/d	OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days
006	Placebo	Placebo capsule once daily for 42 days

Primary Outcome Measures

Name	Time	Method
Change from baseline in the ADHD rating scale total score	Through Day 42

Secondary Outcome Measures

Name	Time	Method
Other secondary endpoints will include the change from baseline in the Conners Adult ADHD Rating Scale (CAARS-S:SV) and the Clinical Global Impression - Severity (CGI-S).	Through the end of the double-blind treatment phase (Day 42)
Secondary endpoints will include Clinical Global Impression of Change (CGI-C).	At the end of the double-blind treatment phase (Day 42)